<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927495</url>
  </required_header>
  <id_info>
    <org_study_id>KN046-IST-01</org_study_id>
    <nct_id>NCT03927495</nct_id>
  </id_info>
  <brief_title>KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Phase II Study of KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma to Evaluate Safety, Efficacy and Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Suzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase II study of KN046 combined with chemotherapy and palliative
      radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to
      evaluate the safety, efficacy and tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-limiting toxicity KN046</measure>
    <time_frame>28 days after first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6-month progression free survival rate assessed by investigator based on RECIST 1.1</measure>
    <time_frame>6 months after first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate assessed by investigator based on RECIST 1.1</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy and KN046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Arm I will receive chemoradiotherapy and concurrent KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemoradiotherapy and sequential KN046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Arm II will receive chemoradiotherapy and sequential KN046. Radiotherapy will be completed within the four-cycle of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN046</intervention_name>
    <description>Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.</description>
    <arm_group_label>Concurrent chemoradiotherapy and KN046</arm_group_label>
    <other_name>Cisplatin+paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>palliative radiotherapy</intervention_name>
    <description>3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.</description>
    <arm_group_label>Concurrent chemoradiotherapy and KN046</arm_group_label>
    <arm_group_label>chemoradiotherapy and sequential KN046</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN046</intervention_name>
    <description>Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.</description>
    <arm_group_label>chemoradiotherapy and sequential KN046</arm_group_label>
    <other_name>Cisplatin+paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed inform consent form(ICF)

          -  Age ≥ 18 years and ≤ 75 years, male or female

          -  Histologically or cytologically documented recurrent or metastatic esophageal squamous
             cell carcinoma, with indications of radiotherapy and without prior systemic treatment

          -  At least one measurable lesion according to Response Evaluation Criteria In Solid
             Tumors（RECISIT） v 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate organ function

          -  Female patients and males with partners of childbearing potential should be using
             highly effective contraceptive measures (failure rate of less than 1% per year).
             Contraception should be continued for a period of 24 weeks after dosing has been
             completed.

          -  Ability to comply with treatment, procedures and pharmacokinetics (PK) sample
             collection and the required study follow-up procedures

        Exclusion Criteria:

          -  Known brain metastasis or another Central Nervous System (CNS) metastasis that is
             either symptomatic or untreated.

          -  Patients who are participating or have participated in a study of an investigational
             drug within 4 weeks prior to the first dose of trial treatment.

          -  Patients who have received immune checkpoint proteins/antibody/medicine for treatment.

          -  Patients who have interstitial lung disease, or a history of pneumonitis that required
             oral or intravenous glucocorticoids to assist with management.

          -  Subjects with active autoimmune diseases or history of autoimmune diseases should be
             excluded

          -  Active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection.

          -  Known HIV infection or known history of acquired immune deficient syndrome (AIDS)

          -  Any unresolved the Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2
             toxicities from prior anti-cancer therapy except for vitiligo, alopecia

          -  Patients who have serious hypersensitive reaction to monoclonal antibodies and have
             history of uncontrolled allergic asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Songbing Qin, MD</last_name>
    <phone>8651267780081</phone>
    <phone_ext>8651267780081</phone_ext>
    <email>sdfyec@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Songbing Qin</last_name>
      <phone>8651267780081</phone>
      <phone_ext>8651267780081</phone_ext>
      <email>sdfyec@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xiaolong Fu</investigator_full_name>
    <investigator_title>Director, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

